http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
-
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
-
Celyad SA (CYAD) Says DFA Authorized Initiation Of THINK Trial in US
-
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
-
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA.
-
Celyad to Present at Cowen and Company 37th Annual Health Care Conference
-
Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial
-
Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial
-
Celyad SA (CYAD) Reports Activation of Second Site in Belgium for THINK Trial
-
Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium
-
Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium
-
Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
-
Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
-
Celyad Announces Registration of the first patient in the Belgian THINK trial
-
Celyad Announces Registration of the First Patient in the Belgian THINK Trial
-
CELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting
-
Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting
-
Celyad SA (CYAD) Receives Approval in Belgium to Commence NKR-2 CAR-T Clinical Trial
-
Celyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium
-
Celyad Announces the Approval to Initiate Its NKR-2 CAR-T Clinical Trial in Belgium
-
Celyad announces third quarter 2016 business update
-
Celyad Announces Third Quarter 2016 Business Update
-
Celyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016
-
Celyad's NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016
-
Celyad’s NKR-2 Phase I Safety Trial Delivers Encouraging Results to Be Presented at ASH 2016
-
CELYAD S.A.: Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa
-
Celyad SA (CYAD) Announces Completion of NKR-2 Phase I in AML
-
CELYAD S.A.: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
-
Celyad Completes the NKR-2 Phase I Trial with Successful Safety Follow-up of the Fourth Dose Level
-
Celyad Reports First Half 2016 Financial Results and Operational Progress
-
Celyad Reports First Half 2016 Financial Results and Operational Progress
-
CELYAD S.A.: Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial
-
Celyad SA (CYAD) Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunotherapy
-
CELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy
-
Celyad Enters into License Agreement with ONO PHARMACEUTICAL CO., LTD. to Develop Allogeneic NKR-2 T-cell Immunotherapy
-
Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure® Cell Therapy
-
CELYAD S.A.: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy
-
Celyad SA (CYAD) Commences Fourth-Level Dosing in NKR-2 Phase 1/2a
-
Celyad Treats First Patient in the Fourth Dose Level of Its NKR-2 Trial
-
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
-
Celyad Successfully Completes Safety Follow-up of the Third Dose Level of its NKR-2 Trial
-
Celyad reports 2015 Financial and Operating results
-
Celyad SA (CYAD) Announces Receipt of U.S. Patent Related to Allogeneic TCR-Deficient CAR T-Cells Production
-
Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-deficient CAR T-cells
-
Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells
-
Celyad to Host an Immuno-Oncology R&D Analyst Day on March 24th in New York City
-
Celyad (CYAD) Completes Safety Follow-Up of Second Dose of Patients in NKR-2 Trial and Enrolls First Patient in Third Dose Level
-
Celyad Successfully Completes Safety Follow-up of the Second Dose Level of Patients in its NKR-2 Trial and Enrolls First Patient in the Third Dose Level
-
Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Patient in the Third Dose Level
-
Celyad: Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination Plan
